Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Assets (2021 - 2025)

Senti Biosciences has reported Assets over the past 5 years, most recently at $51.2 million for Q4 2025.

  • Quarterly results put Assets at $51.2 million for Q4 2025, down 47.65% from a year ago — trailing twelve months through Dec 2025 was $51.2 million (down 47.65% YoY), and the annual figure for FY2025 was $51.2 million, down 47.65%.
  • Assets for Q4 2025 was $51.2 million at Senti Biosciences, down from $52.7 million in the prior quarter.
  • Over the last five years, Assets for SNTI hit a ceiling of $231.9 million in Q2 2021 and a floor of $373657.0 in Q1 2021.
  • Median Assets over the past 5 years was $110.8 million (2023), compared with a mean of $126.0 million.
  • Biggest five-year swings in Assets: soared 61698.89% in 2022 and later tumbled 56.19% in 2024.
  • Senti Biosciences' Assets stood at $96.7 million in 2021, then soared by 86.96% to $180.8 million in 2022, then plummeted by 33.91% to $119.5 million in 2023, then decreased by 18.11% to $97.8 million in 2024, then plummeted by 47.65% to $51.2 million in 2025.
  • The last three reported values for Assets were $51.2 million (Q4 2025), $52.7 million (Q3 2025), and $68.5 million (Q2 2025) per Business Quant data.